CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Following screening, participants with moderate to severe MG were randomized into Period 1 where they received high dose batoclimab (680mg weekly) or lower dose batoclimab (340mg weekly) or placebo ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

and chronic inflammatory demyelinating polyneuropathy (CIDP). Citing topline data, New York-based Immunovant (NASDAQ:IMVT) said its Phase 3 MG trial for the FcRn inhibitor met its primary endpoint in ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

Dianthus Therapeutics ( NASDAQ:DNTH ) Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened by... Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG ...

Thirty-three patients with liver cirrhosis were investigated clinically and electrophysiologically. Nerve-conduction abnormalities were present in 24 (73%) patients compared with 71% reported in a ...

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect Dianthus Therapeutics to ...